|
Hepatoblastoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Hepatoblastoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
beta-catenin mutation and RASSF1A methylation were found in 22 (56.4%) and 15 (38.5%) of 39 hepatoblastomas, respectively, but SFRPs methylation was not found in any of them.
|
16937357 |
2007 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
A further investigation using N- and C-terminal-specific β-catenin antibodies on human hepatoblastomas revealed a correlation between full-length versus truncated β-catenin and differentiation status, with embryonal hepatoblastomas expressing full-length β-catenin and fetal hepatoblastomas expressing β-catenin lacking its N terminus.
|
22613727 |
2012 |
|
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
A histological examination revealed all HBL cases involving tumors without detectable CTNNB1 gene alterations to show high expression of beta-catenin, thus indicating the accumulation of beta-catenin to be a common event in malignant PLTs, including HBL and hepatocellular carcinoma.
|
16465411 |
2006 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
According to recent reports describing beta-catenin mutations (BCM) at hot-spot regions involving exon 3 in several types of malignancies including HB, we investigated BCM in 16 HBs classified into different histological types.
|
11666046 |
2001 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
All 3 (100%) mixed epithelial and mesenchymal HBL harbored CTNNB1 mutation.
|
29079173 |
2017 |
|
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Also, niclosamide, a Food and Drug Administration approved antihelminth compound, could effectively inhibit HB cell growth in vitro and in vivo via downregulation of Dvl-2 and β-catenin expression.
|
29528187 |
2018 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Although mutations in CTNNB1 were not found in the second hepatoblastoma, nuclear accumulation of beta-catenin was detected.
|
14692643 |
2004 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Among human cancers tightly linked to abnormal Wnt/β-catenin signaling, hepatoblastoma (HB) presents with the highest rate (50-90%) of β-catenin mutations.
|
19646548 |
2011 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
By contrast, the expression levels of epithelial-cadherin (E-cadherin) and cytosolic accumulation of β-catenin, the two most prominent markers involved in epithelial-mesenchymal transition (EMT), were reduced in liver specimens from patients with metastatic HB compared with that of healthy adjacent control tissue.
|
25695679 |
2015 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Comparison to previously published data on this series of HB revealed that the number of chromosomal imbalances was significantly higher in HB tumors with loss of heterozygosity on 11p (P = 0.03), whereas in five of 10 HB biopsies without chromosomal imbalances, beta-catenin gene mutations were found.
|
10934159 |
2000 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Correction: mTOR inhibition affects Yap1-β-catenin-induced hepatoblastoma growth and development.
|
31645895 |
2019 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
LHGDN |
Deregulation of the APC/beta-catenin pathway occurs in a consistent fraction of hepatoblastomas, with mutations in the APC and beta-catenin genes implicated in familial adenomatous polyposis-associated and sporadic hepatoblastomas, respectively.
|
17962810 |
2008 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
CTD_human |
Differential expression of glutamine synthetase and cytochrome P450 isoforms in human hepatoblastoma.
|
21237236 |
2011 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we identify lipocalin 2 (Lcn2) as a target of β-catenin and YAP1 in HB and show that serum Lcn2 values positively correlated with tumor burden.
|
29920228 |
2018 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Here, we investigated the oncogenic properties of 14 different HB- and non-HB-associated β-catenin mutants encoded by Sleeping Beauty vectors following their delivery into the mouse liver by hydrodynamic tail-vein injection.
|
31597698 |
2019 |
|
Hepatoblastoma
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
However, variable survival rates of 60-80% and debilitating chemotherapy sequelae argue for more informed treatment selection, which is not possible by grading the Wnt-β-catenin over activity present in most HBL tumors.
|
27910913 |
2016 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis of beta-catenin in 11 HBs demonstrated nuclear/cytoplasmic accumulation of the protein in all tumors analysed, with predominant nuclear beta-catenin immunostaining in undifferentiated cells.
|
10698519 |
2000 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In CTNNB1-mutated hepatoblastoma, expression of GS was only detected in tumour areas with epithelial, not with mesenchymal differentiation.
|
21237236 |
2011 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our data clearly identify protein stabilizing mutations of the β-catenin gene as a common feature of nested stromal epithelial tumors of the liver, similarly as in hepatoblastomas.
|
22749188 |
2012 |
|
Hepatoblastoma
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
In human liver tumor cells without beta-catenin mutations, Nkd-1 inhibited the Wnt-3a-activated Tcf-responsive-luciferase reporter activity, whereas Nkd-1 in hepatoblastomas with beta-catenin mutations had no antagonistic effect.
|
15958610 |
2005 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Interestingly, activating mutations of the beta-catenin gene have previously been identified in 48% of HBs, and more than 85% of HBs show accumulation of beta-catenin protein as the indicator for an activated pathway.
|
12649343 |
2003 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
It is therefore concluded that immunohistochemical analysis of beta-catenin might be a useful clinical tool for estimating the prognosis for patients with hepatoblastoma.
|
11276007 |
2001 |
|
Hepatoblastoma
|
0.700 |
Biomarker
|
disease |
BEFREE |
Moreover, the role of other signaling pathways in hepatoblastoma in association with Wnt/β-catenin has also been described.
|
31511432 |
2019 |